All News

    FDA Grants Drug Designation to Tinostamustine for Malignant Glioma

    November 13th 2025, 5:00pm

    Article

    The FDA has granted orphan drug designation to tinostamustine, an investigational therapeutic, for the treatment of patients with malignant gliomas.

    FDA Approves Komzifti for NPM1-Mutant Acute Myeloid Leukemia

    November 13th 2025, 4:00pm

    Article

    The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.

    Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO

    November 13th 2025, 2:00pm

    Video

    Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

    Cancer Experts Share Emerging Treatments Patients Should Know in 2026

    November 12th 2025, 10:00pm

    Article

    Leading oncology experts share emerging research and developments shaping the year ahead, from precision medicine to innovative cancer therapies.

    Breast Cancer Survivor Advocates for Access to Scalp Cooling

    November 12th 2025, 9:29pm

    Video

    After her own breast cancer treatment, Maureen advocated for legislation to make scalp cooling more accessible for patients seeking to preserve their hair.

    Scalp Cooling Can Prevent Hair Loss During Chemo for Breast Cancer

    November 12th 2025, 8:00pm

    Article

    For Maureen Green, scalp cooling was a crucial part of her breast cancer treatment journey, as it prevented chemotherapy-induced hair loss.

    Have You Taken Time to Grieve? Facing Hearing Loss and Cancer

    November 12th 2025, 6:00pm

    Article

    A survivor shares how hearing loss and cancer deepened her grief, leading her to confront denial and embrace support from her church community.

    Dealing With Peripheral Neuropathy After Breast Cancer Treatment

    November 12th 2025, 5:00pm

    Video

    Ten years after first being diagnosed with breast cancer, Cynthia Malaran said she still faces some side effects from treatment, but she has found strategies for coping.

    Detalimogene Shows 62% Response Rate in Bladder Cancer Trial

    November 12th 2025, 4:00pm

    Article

    Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

    Tracy Milgram-Posner Discusses BRCAStrong and Breast Cancer Support

    November 12th 2025, 2:00pm

    Video

    Tracy Milgram-Posner sat down for an interview with CURE to discuss BRCAStrong and the impact she hopes to make for anyone with breast cancer.